Showing results (121-130 of 156) with videos related to
Sort By:
Pageof 16
Haematologica|August 18, 2025
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trialSara Bringhen, Lorenzo Cani, Nicola Giuliani, et al.Journal of Cancer Research and Clinical Oncology|April 21, 2018
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysisChiara Cerrato, Francesco Di Raimondo, Lorenzo De Paoli, et al.Human Pathology|November 26, 2010
The impact of histopathologic examination of graft-versus-host disease in the era of reduced-intensity conditioning regimen: a study from the Gruppo Italiano Trapianto di Midollo OsseoDaniela Massi, Cristina Fondi, Chiara Nozzoli, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trialAntonio Palumbo, Michele Cavo, Sara Bringhen, et al.Blood|April 14, 2012
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myelomaMichele Cavo, Lucia Pantani, Maria Teresa Petrucci, et al.The Lancet. Haematology|November 26, 2020
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label studyPaola Tacchetti, Lucia Pantani, Francesca Patriarca, et al.BMC Cancer|November 1, 2025
Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision frameworkMario Boccadoro, Angelo Belotti, Felice Bombaci, et al.Eclinicalmedicine|July 3, 2023
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trialElena Zamagni, Stefania Oliva, Francesca Gay, et al.Bone Marrow Transplantation|September 3, 2022
Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamideJacopo Mariotti, Anna Maria Raiola, Andrea Evangelista, et al.The New England Journal of Medicine|January 7, 2016
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host DiseaseNicolaus Kröger, Carlos Solano, Christine Wolschke, et al.Pageof 16